Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

PURPOSES: In this study, we aimed to verify plasma fibroblast growth factor 21 (FGF21) elevation in newly diagnosed overweight patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) and to evaluate the effectiveness of liraglutide on reducing liver fat content and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinyue, Wu, Xiaojuan, Jia, Yumei, Fu, Jing, Zhang, Lin, Jiang, Tao, Liu, Jia, Wang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519721/
https://www.ncbi.nlm.nih.gov/pubmed/34660809
http://dx.doi.org/10.1155/2021/3715026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519721/
https://www.ncbi.nlm.nih.gov/pubmed/34660809
http://dx.doi.org/10.1155/2021/3715026

Ejemplares similares